B- and T-cell markers in opsoclonus–myoclonus syndrome

@article{Pranzatelli2004BAT,
  title={B- and T-cell markers in opsoclonus–myoclonus syndrome},
  author={Michael R Pranzatelli and Anna L. Travelstead and Elizabeth D. Tate and Tyler J. Allison and E. J. Moticka and David Neal Franz and Michael A. Nigro and Julie T. Parke and David A. Stumpf and Steven J. Verhulst},
  journal={Neurology},
  year={2004},
  volume={62},
  pages={1526 - 1532}
}
Background: Although many lines of evidence suggest an autoimmune etiology, the pathophysiology of opsoclonus–myoclonus syndrome (OMS) remains poorly understood and no immunologic abnormalities have correlated with neurologic severity. Conventional immunotherapies often do not prevent relapse or permanent sequelae. Objective: To test the cellular immune hypothesis of OMS in a cross-sectional study and determine if CSF lymphocyte subset analysis provides biomarkers of disease activity. Methods… Expand

Paper Mentions

Observational Clinical Trial
The purpose of this study is to determine if cytokines, inflammatory mediators, are increased in spinal fluid and blood, correlate with disease activity, and could serve as biomarkers… Expand
ConditionsOpsoclonus-myoclonus Syndrome
Functional characterisation of autoantibodies from patients with pediatric opsoclonus–myoclonus-syndrome
TLDR
It is indicated that surface-binding autoantibodies are present in OMS patients and these autoantigens cause inhibition of cell proliferation and induce apoptosis. Expand
Long-Term Cerebrospinal Fluid and Blood Lymphocyte Dynamics After Rituximab for Pediatric Opsoclonus-Myoclonus
TLDR
Data indicate that rituximab affords long-term protection against CSF B cell expansion in OMS, and the observed lag in memory B cell pool recovery in the CSF compared to peripheral blood may be clinically relevant. Expand
6‐Mercaptopurine modifies cerebrospinal fluid T cell abnormalities in paediatric opsoclonus–myoclonus as steroid sparer
TLDR
6‐MP displayed unique pharmacodynamic properties that may be useful in OMS and other autoimmune disorders and its steroid sparer capacity is limited to children in whom the therapeutic window can be reached without limiting pharmacokinetic factors or side effects. Expand
Immunological mechanisms in opsoclonus-myoclonus associated neuroblastoma.
TLDR
The role of different chemokines and their cognate receptors in the recruitment of lymphoid cells within tumor mass of OMS-associated NB is investigated, and the presence of interstitial or perivascular lymphoid infiltrates resembling secondary lymphoid follicles is demonstrated. Expand
Insights on Chronic-Relapsing Opsoclonus-Myoclonus From a Pilot Study of Mycophenolate Mofetil
TLDR
Prior treatment with rituximab prevented relapse-associated increase in cerebrospinal fluid B cells, without hindering mycophenolate mofetil—induced reduction in T-cell activation, demonstrating resistant immunologic problems in chronic-relapsing opsoclonus-myoclonu syndrome. Expand
Trends and tenets in relapsing and progressive opsoclonus-myoclonus syndrome
TLDR
New insights are provided on underappreciated risks and pitfalls inherent in relapse, pro-active efforts to avoid progression, the need for early and sufficient treatment beyond corticosteroids and immunoglobulins, and utilization of disease activity biomarkers to identify high-risk patients and safely withdraw immunotherapy. Expand
Analysis of antibodies to neuronal surface antigens in adult opsoclonus–myoclonus
TLDR
Unlike pediatric OMS, NSA-ab were not detected in adult cases suggesting that the immunity to NSA in OMS is heterogeneous. Expand
Review article Trends and tenets in relapsing and progressive opsoclonus-myoclonus syndrome
TLDR
New insights are provided on underappreciated risks and pitfalls inherent in relapse, pro-active efforts to avoid progression, the need for early and sufficient treatment beyond corticosteroids and immunoglobulins, and utilization of disease activity biomarkers to identify high-risk patients and safely withdraw immunotherapy. Expand
An update on opsoclonus
  • A. Wong
  • Medicine
  • Current opinion in neurology
  • 2007
TLDR
There is increasing recognition that both humoral and cell mediated immune mechanisms are involved in the pathogenesis of opsoclonus, and further studies are needed to further elucidate its immunopathogenesis and pathophysiology in order to develop novel and efficacious therapy. Expand
Cerebrospinal fluid oligoclonal bands in childhood opsoclonus-myoclonus.
TLDR
Cerebrospinal fluid oligoclonal bands warrant monitoring in long-term follow-up studies of disease-modifying drugs for opsoclonus-myoclonous syndrome, and flow cytometry provides a more sensitive measure of B-cell infiltration. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 34 REFERENCES
The immunopharmacology of the opsoclonus-myoclonus syndrome.
TLDR
Recent clinical and laboratory evidence for the autoimmune theory is surveyed and how some current therapies for OMS may exert their effects through immunomodulation is discussed, providing possible new directions for immunologic research and therapy in OMS. Expand
Serum autoantibodies in childhood opsoclonus-myoclonus syndrome: an analysis of antigenic targets in neural tissues.
OBJECTIVE Opsoclonus-myoclonus (OM) is a rare neurologic syndrome affecting children and adults. In children it occurs as a parainfectious process or a paraneoplastic syndrome in association withExpand
Autoantigen diversity in the opsoclonus‐myoclonus syndrome
TLDR
Overall, in the indicated types of OM, frequent and heterogeneous immunity to neuronal autoantigens without a single specific antibody marker of OM is found, and the occasional detection of antibodies to known onconeuronal antigens probably is related to cancer‐induced immunity rather than to OM. Expand
Antineuronal antibodies in patients with neuroblastoma and paraneoplastic opsoclonus-myoclonus.
TLDR
Patients with neuroblastoma and POM are more likely to harbor antineuronal antibodies than patients without POM, but the frequent presence of antineURonal antibodies suggests that POM is immune-mediated. Expand
Screening for autoantibodies in children with opsoclonus-myoclonus-ataxia.
TLDR
It is suggested that anti-Hu, anti-Ri, and anti-Yo do not explain relapses in pediatric opsoclonus-myoclonu-ataxia, and the need to search for unique autoantibodies, as well as cellular mechanisms of pediatric paraneoplastic disease. Expand
Detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration
TLDR
It is suggested that activated cdr2‐specific CTLs in the CSF contribute to Purkinje degeneration in PCD, and that tacrolimus therapy may benefit patients with paraneoplastic neurological disease and other T cell–mediated autoimmune neurological disorders. Expand
Cytotoxic T cells against a peptide of Yo protein in patients with paraneoplastic cerebellar degeneration and anti-Yo antibody
TLDR
CTL activity against a nine-amino acid peptide of the Yo protein peptide expressed on autologous fibroblasts showed CTL activity may be involved in the loss of Purkinje cells in PCD. Expand
Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: histopathologic features-a report from the Children's Cancer Group.
TLDR
Diffuse and extensive lymphocytic infiltration with lymphoid follicles is a characteristic histologic feature of neuroblastic tumors with opsoclonus-myoclonuses, and suggests an immune-mediated mechanism for this rare paraneoplastic syndrome. Expand
PREDOMINANCE OF BORRELIA BURGDORFERI SPECIFIC B CELLS IN CEREBROSPINAL FLUID IN NEUROBORRELIOSIS
TLDR
Evaluation of humoral immunity at the cellular level is a novel approach to the detection and localisation of immune events in neuroinflammatory disorders. Expand
Long-term neurobehavioral outcomes in children with neuroblastoma and opsoclonus-myoclonus-ataxia syndrome: relationship to MRI findings and anti-neuronal antibodies.
TLDR
Certain patients with neuroblastoma associated OMA may achieve average-range neurobehavioral function in spite of residual neurologic abnormalities, with suggestion of continued improvement over time. Expand
...
1
2
3
4
...